MDM2 rs2279744 and TP53 rs1042522 Polymorphisms Associated with Etoposide- and Cisplatin-Induced Grade III/IV Neutropenia in Chinese Extensive-Stage Small-Cell Lung Cancer Patients

Publisher： Karger

E-ISSN： 2296-5262|37|4|176-180

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.4, 2014-03, pp. : 176-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of a 3-Week Schedule of Irinotecan Combined with Cisplatin in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 76-80

Karger

Access to resources Recommend Favorite

Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 34, Iss. 7, 2011-06 ,pp. : 378-381

Karger

Access to resources Recommend Favorite

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 32-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose Escalation Study of Amrubicin in Combination with Fixed-Dose Irinotecan in Patients with Extensive Small-Cell Lung Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 7-11

Karger

Access to resources Recommend Favorite